Elektrofi is a MIT founded biotechnology company in Cambridge, MA working on transforming drug delivery. Founded in 2016, Elektrofi has developed its Elektroject™ platform which is capable of concentrating biologics by greater than 15x, and is using this technology to create a paradigm shift from long duration infusions to quick, cost-effective injections.
The Evans Group
The Evans Group is a team of scientist and engineers who love to tackle challenging problems in biomedical research, clinical practice, and military medicine. We have a passion for developing innovative optical solutions that can be translated rapidly into the hands of researchers, patients, and caregivers. The Evans Group is part of the Wellman Center of Photomedicine, Harvard Medical School at Massachusetts General Hospital, the largest research facility of its kind in the world. The team is highly interdisciplinary and works across the fields of synthetic chemistry, nanoscience, microscopy, and dermatology.
MIT Sandbox provides seed funding for student-initiated entrepreneurship ideas, mentoring from within MIT and from a broad network of committed partners, and tailored educational experiences.
The National Alopecia Areata Foundation
The National Alopecia Areata Foundation (NAAF) serves the community of people affected by an autoimmune skin disease called alopecia areata that results in hair loss and emotional pain. NAAF is a 501-c3 non-profit organization, founded in 1981, with a mission to support research to find a cure or acceptable treatment for alopecia areata, support those with the disease, and educate the public about alopecia areata.
Novopyxis is an award-winning biotechnology company dedicated to the development of therapeutics and medical devices. Their flagship medical device is a patented transdermal delivery system for delivery of drugs up to 60% larger than current treatments deep into skin over large surface areas. The company is located in Kendall Square (Cambridge, USA).
Advancing Innovation in Dermatology
A not-for-profit organization committed to fostering community and innovation in dermatology. AID has created an ecosystem to nurture relationships with individuals and organizations with a common interest in developing and bringing to market practical dermatologic solutions for medical practitioners and their patients.
The Karp Lab
The KarpLab is a training ground for biomedical engineers who aim to change the world with innovative medical products. The lab has a strong track record for advancing novel translatable solutions in the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. Housed at the Brigham and Women’s Hospital, Harvard Medical School, with active affiliations with the Harvard Stem Cell Institute, the Broad Institute and the Harvard-MIT Division of Health Sciences and Technology, the KarpLab has amassed >100 peer-reviewed papers (with >13,000 citations) and >100 issued/pending patents. Several technologies developed in the KarpLab have formed the foundation for multiple products on the market.
Mount Sinai/Joel Dudley Lab
The Dudley Lab focuses on the development and use of translational and biomedical informatics approaches to address critical challenges in systems medicine and biomedical informatics. We are interested in identifying and developing novel therapeutic and diagnostic approaches for human disease through integration and analysis of molecular and clinical data, and also perform research to develop and evaluate methods to incorporate genomic sequencing data into clinical practice.
LEO Pharma Open Innovation
LEO Pharma Open Innovation is a collaborative space created to explore partnerships and collaborations using disease-relevant in vitro assays as an initial stepping stone. The open innovation platform allows insight and access to some of LEO Pharma’s unique research tools in order to test external compounds for disease-relevant effects, but without the external partner having to disclose confidential information or give up intellectual property.
LEO Innovation Lab
LEO Innovation Lab is an independent unit, established by LEO Pharma as part of a long-term strategic decision to focus on patients’ needs by looking at all the aspects of everyday life that can affect a person who has psoriasis. LEO Innovation Lab has been established as a separate entity to create a smaller, more agile organization, where innovation can thrive and solutions be brought to market and tested faster.